Turenne Santé, supported by BNP Paribas Développement, becomes a minority shareholder in the capital of H.A.C.Pharma to support the company in its growth and strengthen the product portfolio

Turenne Santé, the Turenne Groupe Healthcare team, via the FPCI (professional private equity investment fund) Capital Santé 2, as lead manager, and BNP Paribas Développement, take a minority stake in the capital of H.A.C.Pharma, a specialty pharmaceutical laboratory. This operation opening up the capital is part of a new stage of development for the company, which wishes to continue the launch of new drugs and accelerate the expansion of its product portfolio.

Founded in 2007 by Philippe Bissay and Pascal Sery, H.A.C.Pharma, a specialty pharmaceutical laboratory, offers patients a diversified portfolio of essential drugs, orphan drugs and life-saving treatments developed in close collaboration with public and private partners. The group has fifteen specialty drugs in eight different therapeutic areas covering in particular endocrinology, neuropsychiatry, immunology and haematology. This year, the laboratory will launch a new range to meet the needs of patients with epilepsy.

H.A.C.Pharma is recognised for supporting patients in the diagnosis and understanding of their disease, their treatment and their medication compliance. To do this, the laboratory develops new formulations and compliance tools, manages the supply of its product portfolio, promotes the proper use of the drug and takes care of pharmacovigilance monitoring. H.A.C.Pharma also has a network of distributors in various European countries for some of its key drugs.

Positioned in a dynamic sector undergoing significant change, H.A.C.Pharma is entering a new stage in its development by bringing in Turenne Santé and BNPP Développement as  minority shareholders alongside Philippe Bissay, who remains the majority shareholder. The objective is to continue to expand the company’s product range both through portfolio buyouts and through external growth.

Through this minority investment, the FPCI Capital Santé 2 is carrying out its seventh operation in less than three years. As a reminder, Capital Santé 2, a €185M+ fund, whose strategy is to support the growth and address the capital reorganization of profitable FrenchSMEs and mid-cap companies in the healthcare sector and their suppliers.

Philippe Bissay, Chief Executive Officer of H.A.C.Pharma, explains: “BNP has been by our side since the creation of H.A.C.Pharma and we share with the Turenne team a commun vision of our business dedicated to serving healthcare professionals and patients. The arrival of BNP and Turenne is the opportunity for all of our employees to develop our organisation while remaining faithful to our values and capitalising on the talent of our teams. It is a new stage in the history of H.A.C.Pharma with a strong desire to acquire new molecules and develop our portfolio by creating synergies with our current specialties. ”

Mounia Chaoui and Paul Chamoulaud, Turenne Santé, indicate: “We are delighted to be able to support H.A.C.Pharma in its next stage of development. We have been talking for a long time with Philippe Bissay, who has placed his trust in us to pursue, alongside him, the Group’s strategy of developing drugs that best meet the needs of patients. It is on the basis of these solid fundamentals that H.A.C.Pharma has been able to establish its excellent reputation. ”

Frédéric Connault, BNP PARIBAS Développement, specifies: “We are proud to support, alongside Turenne Santé, H.A.C.Pharma in its ambitious and responsible development project led by an experienced and enterprising management team. ”